Defiance Leveraged Long +Income HIMS ETF

Hims & Hers Health Increases Convertible Note Offering to $350 Million

Hims & Hers Health Average Target Price Rises to $27.51

JPMorgan Downgrades Hims & Hers Health's Price Target to $33

Hims & Hers Health Misses Q1 Earnings Estimates, Shares Fall

Oppenheimer & Co. Significantly Reduces Holdings in Hims & Hers Health

Hims & Hers Health's Chief Legal Officer Sold Company Stocks

Hims & Hers Reports FY2025 Revenue and FY2026 Forecast

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

HIMS

HIMY

HIMZ

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

Unusual Whales

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

iShares US Healthcare Providers

SPDR S&P Health

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment | HIMS Stock News

StockTitan

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment | HIMS Stock News

This week, Wall Street saw declines, particularly in technology stocks, while the S&P 500 Health Care Index gained 1.09%. Notable healthcare news includes UnitedHealth's new pharmacy pricing model set for 2027, a $15.2B licensing deal between Bristol Myers Squibb and Hengrui Pharma, and Hims & Hers Health reporting disappointing Q1 results. Additionally, concerns were raised about the potential impact of Trump's drug policy on US biopharma innovation.

businessinsider

Bristol Myers Squibb

Direxion Pharma & Medical Bull 3X

Invesco S&P 500 Equal Weight Health Care ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares US Medical Devices

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

ProShares Ultra Health Care ETF

SPDR S&P Health Equip

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

Hims & Hers Health (NYSE:HIMS) has delivered an average annual return of 20.04% over the past 5 years, outperforming the market by 7.64%. An investment of $1000 in HIMS stock five years ago would now be worth $2,719.87, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $5.74 billion.

benzinga_article

$1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth This Much Today

The stock continues to be very volatile.

Is Hims and Hers Health stock a buy after its latest dip?

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Barchart Option

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

ARMK

EATZ

Top Wall Street analysts have updated their ratings on several companies. Baird raised Aramark's price target from $50 to $58, maintaining an Outperform rating, while Aramark shares closed at $48.41. Other notable changes include BMO Capital increasing Nextpower's target from $113 to $125, and Mizuho cutting Agree Realty's target from $86 to $80. Analysts also adjusted targets for companies like Arvinas, Intellia Therapeutics, and Hims & Hers Health. For a complete list of changes, see the analyst ratings page.

Aramark

AdvisorShares Restaurant ETF

Nextpower

Agree Realty

Arvinas

Intellia Therap

Sensata Tech

ZoomInfo Tech

Aecom

Arteris

AGREE REALTY CORP DEP SHS EA REP 1/1000 CUM PFD STK SR A

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Novo Nordisk partners with Hims & Hers to sell FDA-approved GLP-1 drugs to eligible customers, including Wegovy (injectable and oral) and Ozempic pens; expands retail access to these meds.1Novo Nordisk: once‑weekly semaglutide 2.4 mg cut MACE in SELECT perimenopausal women ~42% vs placebo and ~13% in postmenopausal women; subgroup difference not statistically significant.2

TradingView

Novo Nordisk AS

Defiance Daily Target 2X Long NVO ETF

iShares US Pharma

Key facts: Novo Nordisk sells GLP‑1s via Hims & Hers;MACE down 42%/13%

Hims & Hers (NYSE:HIMS) reported disappointing Q1 2026 earnings, with an EPS of -$0.40, missing expectations of $0.03. Despite a 4% year-over-year revenue increase to $608 million, the stock fell sharply. Investor Tech Stock Pros remains optimistic, citing a growing subscriber base and a positive Q2 revenue guidance of $680-$700 million. HIMS has a consensus Hold rating from Wall Street, with a 12-month price target of $29.22, indicating a 17% upside.

Tip Ranks

'An Attractive Opportunity,' Says Top Investor About Hims & Hers Stock

QURE

VKTX

Today's whale activity in health care stocks reveals significant trading opportunities. Notable options include bullish call sweeps for HIMS, NVO, VKTX, and ELV, with varying expiration dates and strike prices. REPL shows a bullish put trade, while QURE has a bearish call trade. The data indicates abnormal trading volumes, suggesting potential market movements. Traders are advised to monitor these activities closely for investment strategies.

Defiance Leveraged Long +Income HIMS ETF(HIMY.US)

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment | HIMS Stock News

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

$1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth This Much Today

Is Hims and Hers Health stock a buy after its latest dip?